At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 27 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by the Medical University of Vienna, is looking at age-related macular degeneration (AMD), specifically a form called geographic atrophy. It uses artificial intelligence (AI) to monitor areas of the eye not used for sharp central vision, to help spot when the disease gets worse.
Who can take part
- People aged 55 to 99 years.
- Having a specific type of eye change called complete retinal pigment epithelium and outer retinal atrophy (cRORA) — a defined area of thinning and damage in the light-sensitive part of the eye.
- Being able to have clear eye scans, which needs clear eye tissues and pupil widening with drops.
- If both eyes qualify, both may be included.
Who may not be able to
- Eye surgery in the study eye within 3 months before the start of the study.
- Past anti-VEGF injections (a type of eye treatment) in the study eye before the study starts.
- A history of a type of eye swelling called pseudophakic cystoid macular oedema (Irvine Gass syndrome) in the study eye.
- Uncontrolled glaucoma (high eye pressure despite treatment) or a very large cup-to-disc ratio.
- Other eye conditions likely to need treatment or surgery during the study, or that could affect the results.
- Corneal problems such as swelling, cloudiness or scarring affecting best-corrected vision.
- Very strong glasses prescription (more than 6 dioptres), including in the past.
- Taking medicines known to harm the retina, such as hydroxychloroquine or tamoxifen.
- Active new abnormal blood vessel growth in the macula at the start of the study.
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 55 Years to 99 Years
- Who
- All
- Number of participants
- 200
- Started
- 2025-04-11
- Last checked
- 2025-05
Plain English Summary
What is this study?
- • Testing a new treatment for age-related macular degeneration
- • Clinical study - 200 participants
- • The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years
Who can take part?
- • Ages 55 Years to 99 Years
- • Diagnosed with age-related macular degeneration
Where?
- • Belfast - Queen's Unviversity Belfast
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years. The main objectives of this study are: * Assess the individual progression rate of a patient in non-foveal, non-vision compromising atrophic AMD and assess personalized risk of progression based on imaging. * Identify and quantify focal and global alterations in the retina in regard to disease progression. * Evaluate the monitoring of AMD progression using approved AI algorithms. All patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures: * Scanning Laser Fundus Photography * Color Fundus Photography (CFP) * Optical Coherence Tomography (OCT) * Optical Coherence Tomography Angiography (OCTA) Patients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out. No intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 55 Years - 99 Years
- Who can join: All genders
What the study is looking for
- ✓Age: 55-99 years old
- ✓If both eyes are eligible, both eyes will be included in the cohort study.
- ✓Clear optical media and adequate pupillary dilation for imaging and functional testin
Who cannot take part
- ✗Any surgical treatment of the eye within 3 months prior to baseline in the study eye
- ✗History of anti-VEGF treatment in the study eye before baseline
- ✗History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye
- ✗History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment...
- ✗Presence of corneal decompensation, haze or scarring with an impact on BCVA
See the full criteria
Where Is This Study? (1 UK site)
Queen's Unviversity Belfast
Belfast, United Kingdom
How to Get in Touch
Gregor Reiter, Priv.-Doz. Ing. DDr., BA MSc
Sponsor contactCONTACT